<DOC>
	<DOCNO>NCT02885857</DOCNO>
	<brief_summary>Safety efficacy long-term application Shenyankangfu Tablets Large sample patient chronic kidney disease .</brief_summary>
	<brief_title>Safety Efficacy Shenyankangfu Tablets Chronic Kidney Disease</brief_title>
	<detailed_description>Research purpose : Safety efficacy long-term application Shenyankangfu Tablets Large sample patient chronic kidney disease . The crowd : patient primary glomerular nephritis , diabetic nephropathy patient . Study design : multicenter clinical study design , openness . The study drug : Shenyan Kangfu Tablets . Statistical analysis : Research plan determine , statistical professional responsible negotiation principal investigator statistical analysis plan .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . Diagnosed primary glomerulonephritis diabetic nephropathy ; 2 . Aged 18 70 years，male female 3 . GFR≥45ml/min/1.73㎡ 4 . 0.5g≤24 hour proteinuria≤3.0g 5. glycated hemoglobin ( HbAlc ) ≤8 % ( This limit patient diabetic nephropathy ) 6 . Traditional Chinese medicine syndrome conform QiYin Deficiency 7 . Obtain agreement patient guardian , sign informed consent file 1 . Secondary nephropathy 2 . People allergic Shenyankangfu table 3 . Combined severe primary disease heart , brain , liver hematopoietic system , serious disease affect patient 's life 4 . Pregnant lactate woman 5 . Be participate another clinical study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>